TrueCAGR

Mankind Pharma Limited

NSE: MANKINDBSE: 543904ISIN INE634S01028Face value ₹1standalone
₹2,660
+1.14% · 2026-11-20 · 52-wk ₹1,927–₹2,661
Source: BSE filings · Financials to FY2026 · 4 years of history · Data last updated: results filed 26 Oct 2026, prices to 20 Nov 2026 · How we calculate thisconsolidatedstandalone
Section 02 · Synthesis

What stands out?

The strongest observations the engine found, ranked. Every line is generated from the filed numbers by a fixed rule — no opinion, no estimate.

StrengthConcernWatchContext
WatchTalking point

Profit lagging revenue

Revenue grew 17.0% but profit declined 3.6%, so the company kept less of each rupee of revenue as profit.

Revenue growth+17.0%Net profit growth−3.6%

Importance 69 / 95 · growth

WatchTalking point

Growing, but less profitably

Revenue grew 17.0% but EBITDA margin fell 1.3 percentage points to 27.8%, so the company kept less of each rupee of revenue as operating profit.

Revenue growth+17.0%Change in EBITDA margin−1.3 percentage points

Importance 60 / 95 · growth

Concern

Returns declining

ROE declined from 16.7% to 12.5% year on year.

Importance 44 / 95 · profitability

Section 03 · The company

Who is this company?

Classified by the exchange under Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals.

Market cap
₹1.10 L cr
FY2026 revenue
₹10,421 cr
FY2026 net profit
₹2,038 cr
Net worth
₹16,397 cr
Total debt
₹5,571 cr
EPS (basic)
₹49.37
Listed
NSE · BSE
Reporting
Ind-ASApr–Mar

Peer set used on this page: 12 pharmaceuticals.

Section 04 · Business performance

Is the business growing?

Revenue grew 8.6% a year over 3 years, from ₹8,127 cr in FY2023 to ₹10,421 cr in FY2026. Net profit grew 17.7% a year over the same period.

Revenue & net profit — FY23 to FY26₹ crore · consolidated
₹'000 cr05101520023REVENUENET PROFIT8k1,248FY239k1,823FY249k1,945FY2510k2,038FY26
RevenueNet profit
Watch

Revenue grew 17.0% but profit declined 3.6%, so the company kept less of each rupee of revenue as profit.

Rule PROFIT_SLOWER_THAN_REVENUE

Revenue growth per year
+8.6%over 3 years (FY23–FY26)
Revenue growth
+9.7%vs last year
Net profit growth
+4.7%vs last year
Change in net profit since FY23
+63%

Revenue grew 17.0% but EBITDA margin fell 1.3 percentage points to 27.8%, so the company kept less of each rupee of revenue as operating profit.

Revenue grew 17.0% year on year (FY2025 → FY2026).

Section 05 · Recent activity

What changed recently?

In Q2 FY27 (Jul–Sep 2026), revenue was ₹4,338 cr (up 17.3% on the same quarter last year) and net profit ₹716 cr (up 37.7%).

Quarterly results, the trailing-twelve-months snapshot, and verified corporate actions — kept separate from each other and from the annual story above. Every figure traces to a filed number; nothing here is external news or commentary.

Strength

Q2 FY27 net profit was ₹716 cr, up 37.7% from ₹520 cr a year earlier.

Rule QTR_PROFIT_GROWTH_YOY

Strength

Q2 FY27 EBIT was ₹1,030 cr, up 30.2% from ₹791 cr a year earlier.

Rule QTR_OPERATING_PERFORMANCE_CHANGE_YOY

Strength

Q2 FY27 revenue was ₹4,338 cr, up 17.3% from ₹3,697 cr in Q2 FY26 a year earlier.

Rule QTR_REVENUE_GROWTH_YOY

A. Quarterly results

Latest quarters — Q3 '25 to Q2 '27₹ crore · consolidated
₹'000 cr01345001REVENUENET PROFIT3k385Q3 '253k425Q4 '254k445Q1 '264k520Q2 '264k414Q3 '263k559Q4 '264k574Q1 '274k716Q2 '27
RevenueNet profit
QuarterRevenueYoYNet profitYoYNet margin
Q3 FY253,230+23.9%385−16.4%11.9%
Q4 FY253,079+26.1%425−10.9%13.8%
Q1 FY263,570+23.4%445−18.1%12.5%
Q2 FY263,697+20.2%520−21.1%14.1%
Q3 FY263,567+10.4%414+7.6%11.6%
Q4 FY263,443+11.8%559+31.7%16.2%
Q1 FY274,031+12.9%574+29.1%14.2%
Q2 FY274,338+17.3%716+37.7%16.5%

B. TTM snapshot

Trailing twelve months to 30 Sept 2026 · sum of the last 4 contiguous quarters

Revenue
₹15,379 crTTM
EBITDA
₹4,404 crTTM
EBIT
₹3,497 crTTM
PBT
₹2,853 crTTM
Net profit
₹2,264 crTTM

C. Corporate actions

8 Aug 2025DividendInterim Dividend - Rs. - 1.0000 — ₹1.00/share
Section 06 · Business performance

Is it becoming more profitable?

EBITDA margin was 32.7% in FY2026, against 22.9% in FY2023. ROE was 13.1% and ROCE 13.6% in FY2026.

Margins — FY23 to FY26% of revenue · consolidated
0%5%10%15%20%25%30%35%32.7%19.0%FY23FY24FY25FY26
EBITDA marginNet margin
Concern

ROE declined from 16.7% to 12.5% year on year.

Rule ROE_DETERIORATED_YOY

EBITDA margin now
32.7%
4-year range
22.9–32.7%
ROE FY2026
13.1%
ROCE FY2026
13.6%
Section 07 · Financial health

Is financial health improving?

Debt-to-equity was 0.34x in FY2026, against 0.00x in FY2023; interest coverage 5.31x. Operating cash flow was 1.35x net profit.

Net worth — FY23 to FY26₹ crore · consolidated
₹'000 cr0713208kFY2310kFY2415kFY2516kFY26
Net worth (shareholders' funds)
Strength

Debt-to-equity fell from 0.58× to 0.38× year on year.

Rule LEVERAGE_DECREASED_YOY

Operating cash flow vs net profit₹ crore · FY23–FY26
0k1k2k3k2k1kFY232k2kFY242k2kFY253k2kFY26
Operating cash flowNet profit
Total debt
₹5,571 cr
Operating cash flow ÷ net profit
1.35×FY2026
Free cash flow
₹2,418 cr
Current ratio
0.78×
Section 08 · Relative position

How does it compare with peers?

Within its 12-company Pharmaceuticals peer group, it ranks 8 of 12 on return on equity and 7 of 12 on EBITDA margin. Its P/E of 48.5 compares with a peer median of 45.3.

Ranked against 12 pharmaceuticals (FY2026, consolidated). No peer-relative rule fired for this company.

Revenue growth

MANKIND · 5th of 12 · set median 14.8%

GLENMARK27.5%LUPIN23.1%LAURUSLABS22.7%TORNTPHARM21.4%MANKIND17.0%ZYDUSLIFE16.8%DIVISLAB12.8%SUNPHARMA11.2%BIOCON10.9%AUROPHARMA6.1%DRREDDY3.2%CIPLA2.2%

EBITDA margin

MANKIND · 7th of 12 · set median 28.7%

DIVISLAB37.4%SUNPHARMA33.7%ZYDUSLIFE33.1%LUPIN33.1%TORNTPHARM31.9%GLENMARK29.6%MANKIND27.8%LAURUSLABS26.9%CIPLA24.0%DRREDDY23.2%BIOCON22.4%AUROPHARMA21.8%

Return on equity

MANKIND · 8th of 12 · set median 14.4%

LUPIN26.9%ZYDUSLIFE18.3%LAURUSLABS17.7%TORNTPHARM17.0%DIVISLAB16.2%SUNPHARMA14.7%GLENMARK14.1%MANKIND12.5%CIPLA11.7%DRREDDY11.5%AUROPHARMA9.9%BIOCON1.1%

P/E ratio

MANKIND · 7th of 12 · set median 45.3×

LUPIN17.6×AUROPHARMA26.2×ZYDUSLIFE28.1×CIPLA40.1×SUNPHARMA41.2×DRREDDY42.1×MANKIND48.5×GLENMARK51.5×TORNTPHARM75.8×DIVISLAB88.3×LAURUSLABS93.0×BIOCON174.3×
P / E
48.5×TTM to Sept 26
P / B
6.6×latest book
P / S
7.1×TTM sales
Earnings yield
2.1%TTM to Sept 26

On the trailing twelve months. Last full year: P/E 56.7× · P/S 7.5× · ROE 12.5%. TTM and full-year profit differ by more than 15% — a one-off in a recent quarter is moving the trailing figure; weigh it against the full year.

Section 09 · The stock

How has the stock performed?

The share price is up 18.8% over 1 year and up 36.6% over 3 years (11.0% a year). These are price changes excluding dividends, adjusted for splits and bonuses, to 20 Nov 2026; it is at its 52-week high; price history covers less than 5 years.

Adjusted close — 2023-05 to 2026-11₹ per share · split / bonus adjusted
0k4k₹2,6602023202420252026
Context

Over 3 years profit (14.0% a year) and the stock (11.0% a year) compounded at roughly the same rate — the FY2023 base was somewhat depressed, so part of this is recovery rather than trend.

Rule STOCK_TRACKED_EARNINGS · rebound

Business vs stock — 5-year compound annual rate
Net profit14.0%/yrShare price11.0%/yr
1-year return
+18.8%
3-year return
+36.6%
5-year return
—
From 52-wk high
−0.0%
Section 10 · Technical data

What does the technical data say?

Price-action indicators as of 2026-11-20. Secondary to the fundamentals above — included for timing context, not as a signal.

vs 50-day avg
Above₹2,442
vs 200-day avg
Above₹2,343
RSI (14)
64.5neutral
MACD histogram
8.0
From 52-wk high
−0.0%
From 52-wk low
+38.0%
30-day volatility
37.1%ann.
6-month return
+2.9%
RSI (14) · 0–10064.5 — neutral
0305070100OVERSOLDOVERBOUGHT64.5
Section 11 · Open questions

What should I investigate further?

Observations the engine tagged watch or deteriorating — prompts for your own research, not conclusions.

  • Watch
    Profit lagging revenue
    Revenue grew 17.0% but profit declined 3.6%, so the company kept less of each rupee of revenue as profit.
    PROFIT_SLOWER_THAN_REVENUE · conviction 69
  • Watch
    Growing, but less profitably
    Revenue grew 17.0% but EBITDA margin fell 1.3 percentage points to 27.8%, so the company kept less of each rupee of revenue as operating profit.
    REVENUE_UP_MARGIN_DOWN · conviction 60
  • Concern
    Returns declining
    ROE declined from 16.7% to 12.5% year on year.
    ROE_DETERIORATED_YOY · conviction 44
  • Only 4 annual year(s) of financials loaded — multi-year trend analysis is limited.
Section 12 · Reference

The numbers

The full statements, kept deliberately secondary. Every figure traces to a BSE Integrated Filing (inline XBRL); ratios are recomputed from the normalised facts.

Income & balance sheet — ₹ crore, consolidated
MetricFY23FY24FY25FY26
Revenue8,1279,2659,49810,421
Total income8,2909,5319,99110,747
EBITDA1,8602,5923,0563,412
Profit before tax1,5632,2602,3062,315
Net profit1,2481,8231,9452,038
EPS (₹)31.245.547.149.4
Net worth7,7849,62414,64016,397
Total debt597,2545,571
Operating cash flow1,7991,9832,3222,752
Free cash flow1,2561,7992,0312,418
Key ratios — consolidated
RatioFY23FY24FY25FY26
Growth
Revenue growth YoY—14.02.59.7
Profit growth YoY—46.16.74.7
Profitability
EBITDA margin %22.928.032.232.7
Net margin %15.119.119.519.0
Return on equity %16.020.916.013.1
Return on capital %20.426.117.013.6
Leverage & cash
Debt to equity0.000.000.500.34
Cash flow ÷ profit1.441.091.191.35
Current ratio2.543.491.170.78
Financials: BSE Integrated Filing inline XBRL (SEBI taxonomy), normalised to standard metric keys. Prices: end-of-day — history loaded from NSE end-of-day files, new days from the BSE bhavcopy; raw OHLC preserved; a corporate-action factor produces the adjusted series. The insight engine writes factual observations from fixed rules — it does not make recommendations. Not investment advice.